Clinical trials: Pulmonary Hypertension, Primary
Hypertension, Diabetes Mellitus, Type 2
Enhancing Community Health Through Patient Navigation, Advocacy and Social Support
Some patients who have multiple long-term health conditions have significant challenges accessing needed services despite available primary care and social services resources.
- Conditions
- Hypertension, Diabetes Mellitus, Type 2, Chronic Kidney Diseases, Ischemic Heart Disease
- Trial name
- ENCOMPASS (NCT03077386)
- Testing
- ENCOMPASS Intervention
- Where
- Canada
- Volunteers
- 176 people
- Sponsor
- University of Calgary
Pulmonary Arterial Hypertension
Angiotensin Converting Enzyme (ACE2), Brain, Gut Dysbiosis in Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is fatal with right heart failure due to raised pulmonary vascular pressure. Gut dysbiosis was identified in animals with pulmonary hypertension.
- Trial name
- NCT04104490
- Where
- 2 sites in United States, Brazil
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University of Florida
Pulmonary Arterial Hypertension
Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension
Study Rationale:There is recent evidence that HIV protease inhibitors (HIV-PI) can improve pulmonary hemodynamics in experimental models of pulmonary arterial hypertension (PAH).
- Trial name
- NCT02023450
- Testing
- saquinavir and ritonavir
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Third Xiangya Hospital of Central South University
Pulmonary Artery Hypertension
Endothelial Cell Activation and Total Pulmonary Resistance in PAH
To determine whether changes in endothelial cell dysfunction are associated with changes in total pulmonary resistance in patients with pulmonary arterial hypertension
- Trial name
- NCT06035861
- Testing
- XBD173
- Volunteers
- 6 people
- Sponsor
- Imperial College London
Vascular Disease
Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
This open label, single-arm, non-controlled, multicentre study will determine the effect of ambrisentan on exercise capacity (6MWT) in Chinese subjects with PAH.
- Trial name
- NCT01808313
- Testing
- ambrisentan
- Where
- 12 sites in China
- Volunteers
- 134 people
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
Effects of Tracleer (Bosentan) on Pulmonary Arterial Hypertension Related to Eisenmenger Physiology
This study evaluates the effects of bosentan on oxygen saturation, hemodynamics and exercise capacity in patients with pulmonary arterial hypertension related to Eisenmenger physiology.
- Trial name
- NCT00317486
- Testing
- bosentan
- Volunteers
- 54 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
Patients with pulmonary arterial hypertension (PAH) have reduced health related quality of life (HRQOL) and impaired exercise capacity. Despite fourteen approved therapies, most patients die within ten years.
- Trial name
- MOVE PAH) (NCT05464095)
- Testing
- mHealth Intervention, Usual Care
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Vanderbilt University Medical Center
Hypertension, Pulmonary
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial…
- Trial name
- AMBITION (NCT01178073)
- Testing
- ambrisentan, tadalafil
- Where
- 143 sites in United States, Australia and 12 more
- Volunteers
- 610 people
- Sponsor
- GlaxoSmithKline
Hypertension, Pulmonary
Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs
Study to determine the long term safety of tadalafil in patients with increased blood pressure in the blood vessel that carries blood from the right heart to the lungs and to see if it will keep the disease from getting worse.
- Trial name
- NCT00549302
- Testing
- tadalafil
- Where
- 10 sites in United States, Belgium and 8 more
- Volunteers
- 357 people
- Sponsor
- Eli Lilly and Company
Pulmonary Arterial Hypertension
Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers
In this prospective study, the investigators will implement a systematic screening program and 3-year follow-up in a cohort of asymptomatic BMPR2 mutation carriers.
- Trial name
- DELPHI-2 (NCT01600898)
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Takayasu Arteritis With Pulmonary Artery Involvement, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement
The purpose of this study is to identify the clinical features, management pattern and long-term outcomes of patients with pulmonary arteries involvement in Takayasu's arteritis (TAK-PAI).
- Trial name
- CAPTAIN (NCT07184814)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- China-Japan Friendship Hospital
Pulmonary Arterial Hypertension
Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension
This is an open-label, nonrandomized extension to study AC-066A301. The study will assess safety and tolerability of ACT-385781A while providing a means for continuing treatment after ending participation in study AC-066A301.
- Trial name
- Epitome2ext (NCT01470144)
- Testing
- Epoprostenol
- Volunteers
- 41 people
- Sponsor
- Actelion
Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension
the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension
cardiopulmonary exercise test evaluate patients with pulmonary hypertension before and after medical or balloon pulmonary angioplasty treatment
- Conditions
- Pulmonary Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder)
- Trial name
- CPETPH (NCT02061787)
- Testing
- balloon pulmonary angioplasty
- Where
- China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Chinese Pulmonary Vascular Disease Research Group
Pulmonary Arterial Hypertension
FUTURE 3 Study Extension
The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension…
- Trial name
- FUTURE 3 Ext (NCT01338415)
- Testing
- Bosentan
- Where
- 36 sites in United States, Australia and 16 more
- Volunteers
- 58 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension
Patients with symptomatic idiopathic (IPAH) or familial (FPAH) pulmonary arterial hypertension in New York Heart Association (NYHA) class II to IV , naive to PAH treatment or currently being treated with a stable dose of either…
- Trial name
- PROWESS 15 Ext (NCT00709098)
- Testing
- iloprost
- Where
- 34 sites in United States, Austria and 1 more
- Volunteers
- 49 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension
Multi-center, double-blind, placebo-controlled, randomized, parallel study comparing continuous intravenous (IV) Remodulin® to placebo in patients with pulmonary arterial hypertension either primary (PPH) or associated with human…
- Trial name
- TRUST-1 (NCT00494533)
- Testing
- Remodulin (treprostinil sodium)
- Where
- 14 sites in India
- Volunteers
- 45 people
- Sponsor
- United Therapeutics
Congenital Heart Disease, Pulmonary Arterial Hypertension
Biomarkers in Pediatric Congenital Heart Disease and PAH
Nowadays, biomarkers are broadly used in clinical practice. Blood-derived biomarkers fulfil an important role in the field of cardiology. However, most biomarkers have been investigated for adult left ventricular disease.
- Trial name
- NCT04130243
- Testing
- Blood test
- Where
- Netherlands
- Volunteers
- 380 people
- Sponsor
- University Medical Center Groningen
Pulmonary Arterial Hypertension
COMPression of Left Main coRonary artEry in patientS With Pulmonary Arterial Hypertension aSymptomatIc fOr aNgina
The prevalence of critical ab extrinsic compression of left main coronary artery (LMCA) is very high in patients with pulmonary arterial hypertension (PAH) symptomatic for angina (up to 40% according to a recent study of 121…
- Trial name
- COMPRESSION (NCT05413109)
- Testing
- Coronary CT angiography
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hypertension, Pulmonary
First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the strategy of initiating double oral combination therapy with bosentan and sildenafil at the time of diagnosis of pulmonary arterial hypertension (PAH) in a preliminary way.
- Trial name
- NCT01247116
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University of Calgary
Pulmonary Arterial Hypertension
An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
This study provided/continued to provide oral treprostinil (UT-15C SR; treprostinil diethanolamine) to eligible subjects who participated in Studies TDE-PH-202, TDE-PH-203, TDE-PH-205, TDE-PH-301, TDE-PH-302, and TDE-PH-308.
- Trial name
- FREEDOM-EXT (NCT01027949)
- Testing
- Oral Treprostinil
- Where
- 134 sites in United States, Australia and 18 more
- Volunteers
- 894 people
- Sponsor
- United Therapeutics